MoneyWorks4Me

SMS Pharmaceuticals - Quaterly Results

30 May 2025 Evaluate
The total revenue for the quarter ended March 2025 remained nearly unchanged at Rs. 2481.96 millions.An average growth of 29.52% was recorded for the quarter ended March 2025 to Rs. 206.23  millions from Rs. 159.23 millions.The company reported a good operating profit of 427.70 millions compared to 351.33 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 2481.96 2457.98 0.98 7827.48 7092.63 10.36 7827.48 7092.63 10.36
Other Income 14.24 16.46 -13.49 62.24 44.60 39.55 62.24 44.60 39.55
PBIDT 427.70 351.33 21.74 1461.98 1213.04 20.52 1461.98 1213.04 20.52
Interest 50.65 56.09 -9.70 185.41 234.57 -20.96 185.41 234.57 -20.96
PBDT 377.05 295.24 27.71 1276.57 978.47 30.47 1276.57 978.47 30.47
Depreciation 86.40 79.16 9.15 343.37 315.16 8.95 343.37 315.16 8.95
PBT 290.65 216.08 34.51 933.20 663.31 40.69 933.20 663.31 40.69
TAX 84.42 56.85 48.50 249.39 169.07 47.51 249.39 169.07 47.51
Deferred Tax 37.92 10.55 259.43 52.99 17.79 197.86 52.99 17.79 197.86
PAT 206.23 159.23 29.52 683.81 494.24 38.36 683.81 494.24 38.36
Equity 88.65 84.65 4.73 88.65 84.65 4.73 88.65 84.65 4.73
PBIDTM(%) 17.23 14.29 20.56 18.68 17.10 9.21 18.68 17.10 9.21
Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..